BioWorld

Jan. 14, 2004

TKT Says It Will No Longer Seek U.S. Replagal Approval

Transkaryotic Therapies Inc. lost 23.5 percent of its stock value after announcing its decision to abandon efforts to win U.S. approval of Replagal, an enzyme replacement therapy for Fabry's disease. (BioWorld Today) Read More

Curis Inks $170M Deal To License Hedgehog Technology To Wyeth

Synta's Beefy Pipeline Gets $50M In Series C Financing

BioStratum Could Receive $80M Per Antibody In Novo Cancer Deal

Neurogen's C5a Antagonist Fails Phase IIa Asthma Trial

Acumen, Merck Sign Alzheimer's Disease Pact With $96M Potential

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 23, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

Photo of two people shaking hands near lab equipment

K2 nabs two Antengene bispecific TCEs in $2B license, option deal

BioWorld

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...

In the clinic for June 22, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...